MedTrace Logo

Study on Therapy of Non-invasive Prolactinoma

NCT03353025 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 394

Last updated 2017-11-24

No results posted yet for this study

Summary

the study aim to investigate the endocrine remission rate of non-invasive prolactinoma between transsphenoidal surgery treatment and Dopamine agonist treatment.

Conditions

  • Prolactinoma

Interventions

PROCEDURE

transsphenoidal surgery treatment

transsphenoidal surgery treatment

DRUG

dopamine agonist treatment

Minimum effective dose of dopamine agonist，bromocriptine，treat prolactinona

Sponsors & Collaborators

  • First Affiliated Hospital, Sun Yat-Sen University

    lead OTHER

Principal Investigators

  • Haijun Wang, Dr. · First Affiliated Hospital, Sun Yat-Sen University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-01-01
Primary Completion
2025-12-31
Completion
2025-12-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03353025 on ClinicalTrials.gov